Overview Dividends

(INSM) Insmed - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4576693075

Inhaled Antibiotic, DPP1 Inhibitor, Prostacyclin Prodrug, Gene Therapy

INSM EPS (Earnings per Share)

EPS Growth (3Y CAGR): -30.20%
EPS Trend (3Y Correlation): -44.4%

INSM Revenue

Revenue Growth (3Y CAGR): 37.49%
Revenue Trend (3Y Correlation): 93.0%

Risk via 10d forecast
Volatility	35.8%
Value at Risk 5%th	65.0%
Relative Tail Risk	-10.21%

Reward TTM
Sharpe Ratio	2.17
Alpha	164.35

Character TTM
Hurst Exponent	0.504
Beta	0.711
Beta Downside	0.945

Drawdowns 3y
Max DD	30.69%
Mean DD	7.83%
Median DD	7.08%

Description: INSM Insmed October 14, 2025

Insmed Inc. (NASDAQ: INSM) is a biotechnology company focused on developing and commercializing therapies for serious and rare diseases, primarily in the United States, Europe, Japan, and other international markets.

The company’s commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is approved for refractory nontuberculous mycobacterial (NTM) lung infections. Its pipeline includes:

Brensocatib, an oral reversible DPP-1 inhibitor in Phase 3 for bronchiectasis and Phase 2 for chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.
Treprostinil palmitil inhalation powder in Phase 3 for pulmonary hypertension associated with interstitial lung disease and Phase 2 for pulmonary arterial hypertension.
A micro-dystrophin AAV gene-replacement therapy in Phase 1 for Duchenne muscular dystrophy, plus pre-clinical work on next-generation DPP-1 inhibitors, de-immunized proteins, and synthetic rescue platforms.

Financially, Insmed reported Q3 2024 net product revenue of $48 million, driven largely by ARIKAYCE, and held $210 million of cash and marketable securities, giving it roughly 18 months of runway at current burn rates. The company posted a net loss of $78 million for the quarter, reflecting heavy R&D spend (≈ $65 million) and commercial expansion costs.

Key market drivers include the growing prevalence of NTM infections-estimated at > 2 million patients in the U.S.-and the FDA’s Rare Pediatric Disease and Orphan Drug incentives, which can shorten time-to-market and enhance pricing power for niche therapies. The broader biotech sector continues to benefit from elevated capital availability, but valuation multiples remain sensitive to clinical trial outcomes and regulatory timelines.

For a deeper, data-driven valuation, you may find ValueRay’s analytical platform useful.

INSM Stock Overview

Market Cap in USD	40,458m
Sub-Industry	Biotechnology
IPO / Inception	2000-06-01
Return 12m vs S&P 500	137%
Analyst Rating	4.74 of 5

INSM Dividends

Currently no dividends paid

INSM Growth Ratios

CAGR 3y	116.33%
CAGR/Max DD Calmar Ratio	3.79
CAGR/Mean DD Pain Ratio	14.86
Current Volume	2551.4k
Average Volume	2052.8k

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-1.18b TTM) > 0 and > 6% of Revenue (6% = 26.8m TTM)

FCFTA -0.38 (>2.0%) and ΔFCFTA -7.40pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 338.8% (prev 405.5%; Δ -66.67pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.37 (>3.0%) and CFO -883.4m > Net Income -1.18b (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 4.63 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (211.4m) change vs 12m ago 21.71% (target <= -2.0% for YES)

Gross Margin 69.97% (prev 77.25%; Δ -7.28pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 20.26% (prev 16.71%; Δ 3.55pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -12.97 (EBITDA TTM -1.09b / Interest Expense TTM 84.7m) >= 6 (WARN >= 3)

Altman Z'' -10.40

(A) 0.64 = (Total Current Assets 1.93b - Total Current Liabilities 417.2m) / Total Assets 2.36b

(B) -2.25 = Retained Earnings (Balance) -5.31b / Total Assets 2.36b

warn (B) unusual magnitude: -2.25 — check mapping/units

(D) -3.75 = Book Value of Equity -5.30b / Total Liabilities 1.42b

Total Rating: -10.40 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 33.81

1. Piotroski 0.50pt = -4.50

2. FCF Yield -2.29% = -1.15

3. FCF Margin data missing

4. Debt/Equity 0.79 = 2.20

5. Debt/Ebitda -0.38 = -2.50

6. ROIC - WACC (= -84.08)% = -12.50

7. RoE -183.6% = -2.50

8. Rev. Trend 93.00% = 6.97

9. EPS Trend -44.43% = -2.22

What is the price of INSM shares?

As of November 16, 2025, the stock is trading at USD 193.22 with a total of 2,551,400 shares traded.
Over the past week, the price has changed by +1.86%, over one month by +19.73%, over three months by +51.25% and over the past year by +171.15%.

Is Insmed a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Insmed (NASDAQ:INSM) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 33.81 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of INSM is around 221.16 USD . This means that INSM is currently undervalued and has a potential upside of +14.46% (Margin of Safety).

Is INSM a buy, sell or hold?

Insmed has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy INSM.

Strong Buy: 14
Buy: 5
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the INSM price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	208.6	7.9%
Analysts Target Price	208.6	7.9%
ValueRay Target Price	246.7	27.7%

INSM Fundamental Data Overview November 09, 2025

Market Cap USD = 40.46b (40.46b USD * 1.0 USD.USD)
P/S = 90.5056
P/B = 25.8439
Beta = 1.023
Revenue TTM = 447.0m USD
EBIT TTM = -1.10b USD
EBITDA TTM = -1.09b USD
Long Term Debt = 1.10b USD (from longTermDebt, last fiscal year)
Short Term Debt = 12.3m USD (from shortTermDebt, last quarter)
Debt = 745.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 410.3m USD (from netDebt column, last quarter)
Enterprise Value = 39.52b USD (40.46b + Debt 745.1m - CCE 1.68b)
Interest Coverage Ratio = -12.97 (Ebit TTM -1.10b / Interest Expense TTM 84.7m)
FCF Yield = -2.29% (FCF TTM -906.1m / Enterprise Value 39.52b)
FCF Margin = -202.7% (FCF TTM -906.1m / Revenue TTM 447.0m)
Net Margin = -264.8% (Net Income TTM -1.18b / Revenue TTM 447.0m)
Gross Margin = 69.97% ((Revenue TTM 447.0m - Cost of Revenue TTM 134.2m) / Revenue TTM)
Gross Margin QoQ = 58.74% (prev 73.86%)
Tobins Q-Ratio = 16.74 (Enterprise Value 39.52b / Total Assets 2.36b)
Interest Expense / Debt = 2.74% (Interest Expense 20.4m / Debt 745.1m)
Taxrate = -0.36% (negative due to tax credits) (1.32m / -368.7m)
NOPAT = -1.10b (EBIT -1.10b * (1 - -0.36%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 4.63 (Total Current Assets 1.93b / Total Current Liabilities 417.2m)
Debt / Equity = 0.79 (Debt 745.1m / totalStockholderEquity, last quarter 945.6m)
Debt / EBITDA = -0.38 (negative EBITDA) (Net Debt 410.3m / EBITDA -1.09b)
Debt / FCF = -0.45 (negative FCF - burning cash) (Net Debt 410.3m / FCF TTM -906.1m)
Total Stockholder Equity = 645.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -50.15% (Net Income -1.18b / Total Assets 2.36b)
RoE = -183.6% (Net Income TTM -1.18b / Total Stockholder Equity 645.0m)
RoCE = -62.88% (EBIT -1.10b / Capital Employed (Equity 645.0m + L.T.Debt 1.10b))
RoIC = -75.54% (negative operating profit) (NOPAT -1.10b / Invested Capital 1.46b)
WACC = 8.53% (E(40.46b)/V(41.20b) * Re(8.64%) + D(745.1m)/V(41.20b) * Rd(2.74%) * (1-Tc(-0.00)))
Discount Rate = 8.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 20.84%
Fair Price DCF = unknown (Cash Flow -906.1m)
EPS Correlation: -44.43 | EPS CAGR: -30.20% | SUE: -1.64 | # QB: 0
Revenue Correlation: 93.00 | Revenue CAGR: 37.49% | SUE: 4.0 | # QB: 2

Additional Sources for INSM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle